Results 281 to 290 of about 1,940,460 (362)

PF4-associated immune thrombocytopenia and thrombosis (PITT)-More than heparin and vaccines. [PDF]

Br J Haematol
Makris M.
europepmc   +1 more source

Retrospective Evaluation of Blood Product Transfusion Outcomes and Risk Factors for Transfusion Reactions in Dogs at a Veterinary Teaching Hospital with an Established Blood Bank: 137 Dogs (2018–2022)

Journal of Veterinary Emergency and Critical Care, EarlyView.
ABSTRACT Objective To evaluate the outcome of blood transfusions in dogs and identify the incidence of and risk factors associated with transfusion reactions (TRs) classified according to the Association of Veterinary Hematology and Transfusion Medicine (AVHTM) consensus.
Neline G. Holm, Lise N. Nielsen, Rebecca Langhorn   +2 more
wiley   +1 more source

Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report. [PDF]

Clin Case Rep
Bellia M, Moia R, Schipani M, Sella C, Greco M, Al Essa W, Mahmoud AM, Gaidano G, Patriarca A.   +8 more
europepmc   +1 more source

Association of Sarcoidosis and Immune Thrombocytopenia

, 2011
Matthieu Mahévas, Laurent Chiche, Y. Uzunhan, M. Khellaf, A.-S. Morin, G. Le Guenno, Véronique Péronne, Louis Affo, Olivier Lidove, David Boutboul, Geneviève Dion, Jean-Pierre Ducroix, T. Papo, Yves Pachéco, N. Schleinitz, Marc Michel, Bertrand Godeau, Dominique Valeyre   +17 more
openalex   +1 more source

ESM‐1 and GBP‐1 are associated with endothelial dysfunction: emerging biomarkers or key players in the pathophysiology of preeclampsia?

The Journal of Physiology, EarlyView.
Abstract figure legend Endothelial specific molecule‐1 (ESM‐1) and guanylate binding protein‐1 (GBP‐1) are proteins that are produced by activated/dysfunctional endothelial cells and are increased and decreased, respectively, during preeclampsia. It remains to be established whether ESM‐1 and GBP‐1 could potentially be included as biomarkers for the ...
Ines Pronk, Joost H. N. Schuitemaker, Marijke M. Faas, Alexandra M. Smink   +3 more
wiley   +1 more source

Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus. [PDF]

EJHaem
Bradbury C, Thachil J, McWilliams M, Lester WA.   +3 more
europepmc   +1 more source

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody–mediated amelioration of murine immune thrombocytopenia

, 2011
Andrew R. Crow, Sara J. Suppa, Xi Chen, Patrick J. Mott, Alan H. Lazarus   +4 more
openalex   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source

Primary renal mucosa-associated lymphoid tissue lymphoma coexisting with immune thrombocytopenia. [PDF]

World J Surg Oncol
He J, Deng C, Huang Y, Wang M, Wei C, Xu F, Chen R, Wang J, Yang M, Chen Z.   +9 more
europepmc   +1 more source